Enhanced oral bioavailability of paclitaxel by recombinant interleukin-2 in mice with murine Lewis lung carcinoma

Drug Metabolism and Drug Interactions

Volumn 20, Issue 4, 2004, Pages 219-231

  Abbara, Chadi ^a   Rouchon, Christophe ^a   Hosten, Benoît ^b   Farinotti, Robert ^b   Bonhomme Faivre, Laurence ^a,b  

^a HÔPITAL PAUL BROUSSE   (France)

^b Facult de Pharmacie de Chtenay Malabry   (France)

Author keywords

Bioavailability; P glycoprotein; Paclitaxel; Pharmacokinetics; Recombinant interleukin 2

Indexed keywords

DOCETAXEL; GLYCOPROTEIN P; PACLITAXEL; RECOMBINANT INTERLEUKIN 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CLINICAL PRACTICE; COMPUTER PROGRAM; CONTROLLED STUDY; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INHIBITION; INTESTINE ABSORPTION; LEWIS CARCINOMA; LUNG CANCER; MOUSE; NONHUMAN; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY;

EID: 11444257020     PISSN: 07925077     EISSN: None     Source Type: Journal    
DOI: 10.1515/DMDI.2004.20.4.219     Document Type: Article

References (29)

1. Rowinsky EK, Wright M, Monssarat B, Lesser GJ, Donehower RC. Taxol: pharmacology, metabolism and clinical implications. Cancer Surv 1993; 17: 283-301.
2. Gianni L, Kearns CM, Giani A, Capri G, Vigano L, Lacatelli A, et al. Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetics/pharmacodynamic relationship in humans. J Clin Oncol 1995; 13: 180-190.
3. Sparreboom A, Van Tellingen O, Nooijen WJ, Beijnen JH. Tissue distribution, metabolism and excretion of paclitaxel in mice. Anticancer Drugs 1996; 7: 78-86.
4. van Tellingen O, Huizing MT, Panday VR, Schellens JH, Nooijen WJ, Beijnen JH. Cremophor EL causes (pseudo-) non-linear pharmacokinetics of paclitaxel in patients. Br J Cancer 1999; 81: 330-335.
5. Malingré MM, Beijnen JH, Rosing H, Koopman FJ, van Tellingen O, Duchin K, et al. A phase I and pharmacokinetics study of bidaily dosing of oral paclitaxel in combination with cyclosporine A. Cancer Chemother Pharmacol 2001; 47: 347-354.
6. Sparreboom A, van Asperen J, Mayer U, Schinkel AH, Smit JW, Meij DK, et al. Limited oral bioavailability and active epithelial excretion of paclitaxel caused by P-glycoprotein in intestine. Proc Natl Acad Sci USA 1997; 94: 2031-2035.
7. Malingré MM, Beijnen JH, Schellens JHM. Oral delivery of taxanes. Invest New Drugs 2001; 19: 155-162.
8. Gottesman MM, Pastan I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem 1993; 62: 385-427.
9. Bradley G, Ling V. P-glycoprotein, multidrug resistance and tumor progression. Cancer Metastasis Rev 1994; 13: 223-233.
10. Jachez B, Nordamin R, Loor F. Restoration of taxol sensitivity of multi-drug-resistant cells by the cyclosporine SDZ PSC 833 and the cyclopeptolide SDZ 280-446. J Natl Cancer Inst 1993; 85: 478-483.
11. Cardarelli CO, Aksentijerich I, Pastan I, Gottesman MM. Differential effects of P-glycoprotein inhibitors on NIH3T3 cells transfected with wild type (G 185) or mutant (V185) multidrug transporters. Cancer Res 1995; 55: 1086-1091.
12. Drach J, Gsur A, Hamilton G, Zhao S, Angerler J, Fiegl M, et al. Involvement of P-glycoprotein in the transmembrane transport of interleukin-2 (IL-2), IL-4 and interferon-gamma in normal human T lymphocytes. Blood 1996; 88: 1747-1754.
13. Stein U, Wather W, Shoemaker RH. Modulation of mdr1 expression by cytokines in human colon carcinoma cells: an approach for reversal of multidrug resistance. Br J Cancer 1996; 74: 1384-1391.
14. Bonhomme-Favire L, Pelloquin A, Tardivel S, Saik U, Mathieu MC, Castagne V, et al. Recombinant interleukin-2 treatment decreases P-glycoprotein activity and paclitaxel metabolism in mice. Anti-Cancer Drugs 2002; 13: 51-57.
15. van Asperen J, van Tellingen O, van der Valk MA, Rozenhart M, Beijnen JH. Enhanced oral absorption and decreased elimination of paclitaxel in mice cotreated with cyclosporine A. Clin Cancer Res 1998; 4: 2293-2297.
16. Meerum Terwogt JM, Malingré MM, Beijnen JH, ten Bokkel Huinink WW, Rosing H, Koopman FJ, et al. Coadministration of oral cyclosporine A enables oral therapy with paclitaxel. Clin Cancer Res 1999; 5: 3379-3384.
17. van Asperen J, van Tellingen O, Sparreboom A, Schinkel AH, Borst P, Nooijen WJ, et al. Enhanced oral bioavailability of paclitaxel in mice treated with the P-glycoprotein blocker SDZ PSC 833. Br J Cancer 1997; 76: 1181-1183.
18. Bardelmeijer HA, Beijnen JH, Brouwer KR, Rosing H, Nooijen WJ, Schellens JH, et al. Increased oral bioavailability of paclitaxel by GF120918 in mice through selective modulation of P-glycoprotein. Clin Cancer Res 2000; 6: 4416-4421.
19. Willey TA, Bekos EJ, Gaver RC, Duncan GF, Tay LK, Beijnen JH, et al. High performance liquid chromatographic procedure for the quantitative determination of paclitaxel (Taxol®) in human plasma. J Chromatogr 1993; 621: 231-238.
20. Urien S. MicroPharm-K, a microcomputer interactive program for the analysis and simulation of pharmacokinetic process. Pharm Res 1995; 12: 1225-1230.
21. Burtin P, Mentré F, Van Bree J, Steimer JL. Sparse sampling for assessment of drug exposure in toxicological studies. Eur J Drug Metab Pharmacokinet 1996; 21: 105-111.
22. Bailer AJ. Testing for the equality of area under the curves when using destructive measurement techniques. J Pharmacokinet Biopharm 1988; 3: 303-309.
23. Shah VP, Midha KK, Dighe SV. Workshop Report. Pharm Res 1992; 9: 588-592.
24. Rowinsky EK, Wright M, Monssarat B, Donehower RC. Clinical pharmacology and metabolism of Taxol (paclitaxel): update 1993. Ann Oncol 1994; 5 (Suppl 6): S7-S16.
25. Sonnichsen DS, Liu Q, Schuetz EG, Schuetz JD, Pappo A, Relling MV. Variability in human cytochrome P450 paclitaxel metabolism. J Pharmacol Exp Ther 1995; 275: 566-575.
26. Walle T, Walle K, Kumar GN, Bhalla KN. Taxol metabolism and disposition in cancer patients. Drug Metab Dispos 1995; 23: 506-512.
27. Penzak SR, Shen JM, Alfaro RM, Remaley AT, Natarajan V, Falloon J. Ritonavir decreases the nonrenal clearance of digoxin in healthy volunteers with known MDR1 genotypes. Ther Drug Monit 2004; 26: 322-330.
28. Sham HL, Kempf DJ, Molla A, Marsh KC, Kumar GN, Chen CM, et al. ABT-378, a highly potent inhibitor of the human immunodeficiency virus protease. Antimicrob Agents Chemother 1998; 42: 3218-3324.
29. Veau C, Faivre L, Tardivel S, Soursac M, Banide H, Lacour B, et al. Effect of interleukin-2 on intestinal P-glycoprotein expression and functionality in mice. J Pharmacol Exp Ther 2002; 302: 742-750.